RS
TSHA icon

R Squared’s Taysha Gene Therapies TSHA Stock Holding History

R Squared’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50.4K Buy
+11,276
New +$52.4K 0.03% 417
2025
Q4 		– Sell
-16,094
Closed -$52.6K – 718
2025
Q3 		$52.6K Buy
+16,094
New +$45.6K 0.02% 487
2025
Q1 		– Sell
-130
Closed -$225 – 1428
2024
Q4 		$225 Buy
+130
New +$270 ﹤0.01% 1556

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

R Squared's TSHA Position: Q1 2026 in Review

R Squared opened a new position in Taysha Gene Therapies (TSHA) in Q1 2026: 11,276 shares worth $50.4K. The stake represents 0.03% of the portfolio and ranks #417 among its holdings. This is a return to the name: R Squared previously reported a position in TSHA as recently as Q3 2025.

R Squared first reported a position in TSHA in Q4 2024 and has held it in 3 quarters since. The position peaked at $52.6K in Q3 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • R Squared held 11,276 shares of Taysha Gene Therapies worth $50.4K as of Q1 2026.
  • Taysha Gene Therapies was a new R Squared position in Q1 2026.
  • Taysha Gene Therapies made up 0.03% of R Squared's portfolio in Q1 2026, its #417 holding.
  • R Squared first reported a position in Taysha Gene Therapies in Q4 2024 and has held it in 3 quarters since.
  • R Squared's Taysha Gene Therapies position peaked at $52.6K in Q3 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.